Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate (DAC) plat...
J&J makes $1B bet on emerging DAC space by netting Firefly Bio
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate (DAC) platform via the acquisition of Firefly Bio.
Author: Fierce Biotech
Read Original Article